MedPath

Itraconazole

Generic Name
Itraconazole
Brand Names
Sporanox, Tolsura
Drug Type
Small Molecule
Chemical Formula
C35H38Cl2N8O4
CAS Number
84625-61-6
Unique Ingredient Identifier
304NUG5GF4
Background

One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.

Indication

For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Associated Conditions
Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
Clinical Trials
Related News

Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects

Phase 1
Completed
Conditions
NSCLC
Interventions
First Posted Date
2023-06-15
Last Posted Date
2024-04-05
Lead Sponsor
Shanghai Henlius Biotech
Target Recruit Count
20
Registration Number
NCT05902728
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Efficacy and Safety of Terbinafine and Itraconazole

Phase 2
Not yet recruiting
Conditions
Tinea Corporis
Tinea Cruris
Tinea Faciei
Dermatophytoses
Interventions
First Posted Date
2023-05-31
Last Posted Date
2023-05-31
Lead Sponsor
Dhaka Medical College
Target Recruit Count
150
Registration Number
NCT05881980

Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor

Phase 1
Completed
Conditions
Tinea Versicolor
Interventions
First Posted Date
2023-05-17
Last Posted Date
2023-05-17
Lead Sponsor
Combined Military Hospital Abbottabad
Target Recruit Count
164
Registration Number
NCT05862714
Locations
🇵🇰

CMH Abbottabad, Abbottābād, Khyber Pakhtunkhwa, Pakistan

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2023-05-16
Last Posted Date
2024-11-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
30
Registration Number
NCT05860933
Locations
🇺🇸

ICON Early Development Services, Salt Lake City, Utah, United States

A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

Phase 1
Completed
Conditions
COVID-19
Interventions
Drug: Placebo
Drug: ALG-097558 in solution formulation
Drug: ALG-097558 in tablet formulation
First Posted Date
2023-05-03
Last Posted Date
2025-04-08
Lead Sponsor
Aligos Therapeutics
Target Recruit Count
90
Registration Number
NCT05840952
Locations
🇬🇧

Hammersmith Medicines Research, London, United Kingdom

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1810631 in the Blood

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2023-04-27
Last Posted Date
2024-10-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT05833139
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2023-04-20
Last Posted Date
2024-10-04
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT05822440
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

Phase 1
Completed
Conditions
Amyotrophic Lateral Sclerosis
Healthy Volunteer
Interventions
First Posted Date
2023-04-04
Last Posted Date
2025-01-03
Lead Sponsor
Sanofi
Target Recruit Count
16
Registration Number
NCT05797753
Locations
🇺🇸

Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States

A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2023-03-29
Last Posted Date
2023-11-14
Lead Sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Target Recruit Count
54
Registration Number
NCT05789342
Locations
🇨🇳

China-Japan Friendship Hospital, Beijing, China

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

Phase 1
Completed
Conditions
Healthy
Interventions
Device: Cyclosporine
First Posted Date
2023-02-27
Last Posted Date
2023-06-27
Lead Sponsor
Pfizer
Target Recruit Count
16
Registration Number
NCT05745701
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy